Latest Press Releases
April 22, 2017
NGM Bio Announces NGM282 Dramatically Reduced Liver Fat and Other Biomarkers Associated with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial
Presentation – Stephen A. Harrison, M.D.
NGM282, a Novel Variant of FGF19, Significantly Reduces Hepatic Steatosis and Key Biomarkers of NASH: Results of a Phase 2, Multicenter, Randomized, Double-Blinded, Placebo Controlled Trial in Biopsy-Confirmed NASH Patients
April 5, 2017
NGM Bio to Present Phase 2 Data of NGM282 in NASH at International Liver Congress 2017
June 8, 2016
NGM Bio Initiates Phase 1 Clinical Trial of NGM313, a Proprietary Antibody with the Potential to Treat Type 2 Diabetes, Obesity and NASH
November 9, 2015
NGM Bio to Present Data Highlighting the Therapeutic Potential of NGM282 in Cholestatic Liver Diseases at AASLD’s The Liver Meeting® 2015
There are no webcast at this time.
Media Inquiries: email@example.com